Donate now, support IFFGD

My Cart | Register | Sign In

Header Image

Industry Treatment News

This page lists treatment news from IFFGD Industry Council Members. No endorsement is intended or implied.

Clinical Studies Seeking Participants

A clinical study or trial is a research study to answer specific questions about new therapies or new ways of using known treatments.

Linaclotide Study for IBS-C in Children

March 22, 2016 – Participants sought for a multicenter, randomized, double-blind, placebo-controlled safety and efficacy study of a range of linaclotide doses administered orally to children ages 7 to 17 years, with irritable bowel syndrome with constipation (IBS-C). The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C), in children ages 7-17 years. Learn more

Linaclotide Study for FC in Children

March 22, 2016 – Participants sought for a multicenter, randomized, double-blind, placebo-controlled parallel-group, safety and efficacy study of a range of linaclotide doses administered orally to children, ages 6 to 17 years, who fulfill modified Rome III Criteria for child/adolescent functional constipation (FC). The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of functional constipation (FC), in children ages 6-17 years. Learn more

CSID Genetic Prevalence Study

October 8, 2014 – Participants aged 18 or younger are being sought for a research study that could help your child and others who are experiencing chronic diarrhea and/or abdominal pain due to a possible deficiency in table sugar digestion. Learn more

Long-Term Study of SBS

March 3, 2014 – Participants of any age are being sought for a long-term research study of patients with short bowel syndrome (SBS). Learn more

Treatment News

Developments in drug treatments for functional GI and motility disorders.

Eluxadoline

December 16, 2015 – Allergan has announced the availability of eluxadoline (Viberzi) by prescription in the US for the treatment of IBS-D. Learn more

Linaclotide (Linzess/Constella)

December 15, 2015 –  Positive results announced for Phase III Clinical Trial of Linaclotide in Japan for treatment of adults with irritable bowel syndrome with constipation (IBS-C). Learn more

Teduglutide

January 5, 2015 – The Japanese Ministry of Health, Labor, and Welfare (MHLW) granted teduglutide (Gattex in the US; Revestive in the EU) orphan drug status for the treatment of adult patients with short bowel syndrome (SBS). Teduglutide

June 30, 2014 – The U.S. Food and Drug Administration (FDA) has approved updated labeling for Gattex (teduglutide [rDNA origin]) for injection, to include long-term data from adult patients with Short Bowel Syndrome (SBS). Learn more

Linaclotide (Linzess/Constella)

June 13, 2013 – Linaclotide is now available in Europe (branded as Costella in the EU) to treat irritable bowel syndrome with constipation (IBS-C)Learn more

 

 

Last modified on May 1, 2016 at 07:32:30 AM